GlassScriptPhysician profile
Munira Mehta
NPI 1205129350
$2,032.82
in general payments reported to CMS, 2019-2025
25 companies · $231 in 2025
The $231 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.49 · 2020: $231 · 2021: $589 · 2022: $627 · 2023: $298 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $528.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $349.82 | 2019-2023 | Mounjaro |
| Medtronic, INC. | $191.55 | 2021-2023 | Inpen Smart Insulin Delivery System |
| Tandem Diabetes Care, INC. | $160.06 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $152.83 | 2021-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Mannkind Corporation | $144.98 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $134.01 | 2025 | |
| Novo Nordisk INC | $121.32 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $106.64 | 2019-2022 | |
| Corcept Therapeutics | $98.28 | 2021-2023 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.46 | 2020-2023 | Jardiance |
| Grt US Holding, INC. | $86.60 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $64.69 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $43.05 | 2020-2022 | |
| Abbott Laboratories | $41.82 | 2022-2023 | Freestyle Libre 3 |
| Radius Health, INC. | $39.76 | 2021-2023 | Tymlos |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $38.38 | 2021 | |
| Ibsa Pharma INC. | $26.49 | 2020-2023 | Tirosint, Licart |
| Merck Sharp & Dohme LLC | $24.30 | 2020-2021 | |
| Nevro Corp. | $21.80 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.34 | 2022 | |
| Vivus LLC | $17.01 | 2021 | |
| Averitas Pharma INC. | $16.21 | 2023 | Qutenza |
| Xeris Pharmaceuticals, INC. | $15.73 | 2022 | |
| Currax Pharmaceuticals LLC | $14.43 | 2023 | Contrave |
| Intuity Medical INC | $13.26 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munira Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.